TN
Tango Therapeutics, Inc.
TNGX · NASDAQ
$22.33 +1.36% (+$0.30)
1M -8.89%
Market Cap $3.82B
P/E Ratio -
Div. Yield -
ROE 25.74%
Piotroski F-Score Weak
2/9Valuation
27 /100
Expensive P/B 3.73x
P/S 71.07x
PEG N/A
Growth
97 /100
Growing Book val. growth 11.54%
Rev. growth 35.89%
FCF growth N/A
Profitability
20 /100
Weak FCF margin 268.10%
Op. margin 253.38%
Gross margin 98.25%
Quality
1 /100
Poor Asset turnover 0.05x
ROA 11.52%
ROIC 12.90%
Debt
100 /100
Low Current ratio 50.82x
Debt/Equity 0.03x
Net debt/EBITDA N/A
Stability
64 /100
Moderate Profitable years 0
EPS volatility 18.67%
Beta 1.12x
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na TNGX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Malte Peters
Employees
137
Headquarters
Boston
Nadcházející události
03 LIS
Earnings
Upcoming earnings report